Actelion receives Canada approval for Uptravi
ZURICH – Actelion Ltd, Europe’s biggest biotech firm, said on Tuesday that Health Canada had granted a notice of compliance for Uptravi, a new pulmonary arterial hypertension medicine.
The approval is “a major milestone”, Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada “as soon as possible”.
Analysts have said Uptravi could reap more than $1 billion in global sales annually at its peak. -Reuters